AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04301804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: a selective small-molecule CDK4/6 inhibitor
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0941 Matching Placebo
Description: Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01437566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC-0980 Matching Placebo
Description: Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Study NCT01662609 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound (EUS)
Description: Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
Study NCT01963078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01963078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04873219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manufacturing a complete dental prosthesis
Description: dental treatment to replace missing teeth
Study NCT04873219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manufacturing a complete dental prosthesis
Description: dental treatment to replace missing teeth
Study NCT00586417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punch biopsy
Description: skin biopsies
Study NCT04830319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Method
Description: includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
Study NCT04830319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Method
Description: includes exercises in soil, that associate the correct respiratory movement with muscular strengthening and control, stretching from the eccentric movement, selective upper and lower trunk movements. There will be used accessories described by the method for their realization. Participants will perform the first week of awareness and body alignment exercises for 10 minutes, 10 minute breath perception, 10 minute proximal muscle accuracy and control, and 10 minute stretches; from the second week will be included selective trunk movements, with muscle strengthening of lower limbs. Rest intervals will be performed between exercises.
Study NCT04830319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented training protocol
Description: The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
Study NCT04830319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-oriented training protocol
Description: The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
Study NCT03031015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented K-wire Fixation
Description: Fractures were reduced and then fixed with cemented K-wires.
Study NCT03031015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented K-wire Fixation
Description: Fractures were reduced and then fixed with cemented K-wires.
Study NCT03031015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plating
Description: Fractures were reduced and then fixed with Plate.
Study NCT03031015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plating
Description: Fractures were reduced and then fixed with Plate.
Study NCT00934362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lucinactant first
Description: lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
Study NCT00934362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo first
Description: 6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
Study NCT03917953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3).
Study NCT03917953 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Acupoint Stimulation
Description: Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupoints without electrical stimulation).~Acupoint selection: baihui (GV 20), taichong (LR 3), taixi (KI 3).
Study NCT04239391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Ferric Pyrophosphate Citrate
Study NCT00499083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
Study NCT00499083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase inhibition therapy
Description: Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Study NCT00499083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV day 1 every 2 weeks for 4 cycles
Study NCT00499083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2 IV day 1 every 2 weeks for 4 cycles
Study NCT00499083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
Study NCT00499083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Study NCT00499083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
Study NCT00499083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
Study NCT00499083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
Study NCT00499083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
Study NCT00499083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
Study NCT00499083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
Study NCT00499083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Study NCT00499083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
Study NCT00499083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
Study NCT00499083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
Study NCT00499083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
Study NCT01278212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated hypofractionated radiotherapy (AHF-RT)
Description: 30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
Study NCT02835976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olesoxime
Description: Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
Study NCT00946621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg Capsule (Sandoz)
Study NCT00946621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
Study NCT02295670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vividtrac
Description: video-laryngoscopy
Study NCT02295670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: direct-laryngoscopy
Study NCT04462614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decrease per-dialytic heparin therapy
Description: Week 1: maintenance's dose stop Week 2: 50% drop in the loading dose Week 3: complete cessation of heparin therapy during the session.
Study NCT02296645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.
Study NCT02296645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.
Study NCT03048578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
Study NCT03048578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Saline Solution
Study NCT02861001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bronchoscopy
Description: optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
Study NCT02861001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight-SL tube
Description: optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
Study NCT03777891 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phonophoresis with different material
Description: phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
Study NCT03898557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of HIV self-test with Commitment and planning prompts
Description: The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
Study NCT03898557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of HIV self-test
Description: This arm will receive a HIV self-test
Study NCT01829152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHM
Study NCT00552435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Laser therapy is applied using a slit lamp and specific laser contact lens.
Study NCT00552435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser therapy is applied using a slit lamp and specific laser contact lens.
Study NCT02428725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
Study NCT04189887 — intervention group
Intervention type: BEHAVIORAL
Intervention: aerobic exercise (cycling)
Description: People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning
Study NCT04189887 — intervention group
Intervention type: BEHAVIORAL
Intervention: Implicit sequence learning
Description: All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
Study NCT02471599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy
Description: The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
Study NCT02471599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-tonsillectomy
Description: The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
Study NCT01572285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal dexamethasone injection
Description: Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml